Skip to main content
Home > The Daily Extra > Company News

Chronological Index of BioCentury Extra, The Daily News: Company News

BioCentury Extra, The Daily News Current Issue
  • COMPANY NEWS: AMAG slides on Rienso recall in Switzerland

    AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) fell $2.68 (11%) to $22.40 on Wednesday after disclosing in an SEC filing that partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) is recalling a batch of anemia drug Rienso …

    Published on 5/22/2013
  • COMPANY NEWS: BARDA awards GSK up to $200M for antibacterials

    HHS's Biomedical Advanced Research and Development Authority (BARDA) awarded GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) $40 million for an initial 18-month period to develop GSK's portfolio of antibacterial candidates to …

    Published on 5/22/2013
  • COMPANY NEWS: FDA to discuss Lotronex's REMS

    FDA's Drug Safety and Risk Management Advisory Committee will meet on July 10 to discuss the REMS with elements of safe use (ETASU) for Lotronex alosetron from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and partner …

    Published on 5/22/2013
  • COMPANY NEWS: Biogen submits Plegridy BLA for MS

    Biogen Idec Inc. (NASDAQ:BIIB) submitted a BLA to FDA for Plegridy peginterferon beta-1a (BIIB017) to treat relapsing forms of multiple sclerosis (MS). The company said it expects to submit MAA to EMA "in the coming …

    Published on 5/21/2013
  • COMPANY NEWS: EC approves Baxter's HyQvia

    The European Commission approved an MAA from Baxter International Inc. (NYSE:BAX) for HyQvia as replacement therapy for adults with primary immunodeficiencies. The product is also approved as replacement therapy in …

    Published on 5/21/2013
  • COMPANY NEWS: EMA accepts MAA for LCP-Tacro

    Veloxis Pharmaceuticals A/S (CSE:VELO) said EMA accepted for review an MAA for LCP-Tacro tacrolimus to prevent organ rejection in kidney transplant patients. The company said it expects a decision on the application …

    Published on 5/21/2013
  • COMPANY NEWS: EMA grants accelerated assessment to Gilead's sofosbuvir

    Gilead Sciences Inc. (NASDAQ:GILD) said EMA accepted for accelerated assessment an MAA for sofosbuvir to treat chronic HCV infection. An accelerated assessment shortens the review period to 150 days from 210. Gilead …

    Published on 5/21/2013
  • COMPANY NEWS: Novo A/S acquires Xellia

    Novo A/S (Hellerup, Denmark) will acquire infectious disease company Xellia Pharmaceuticals A/S (Oslo, Norway) from private equity firm 3i Group for about $700 million. In 2008, 3i acquired Xellia, which develops and …

    Published on 5/21/2013
  • COMPANY NEWS: Roche declines to exercise STX209 option

    Roche (SIX:ROG; OTCQX:RHHBY) said it declined to exercise its option to license STX209 from Seaside Therapeutics Inc. (Cambridge, Mass.) for autism after Seaside reported earlier this month that the compound missed the …

    Published on 5/21/2013
  • COMPANY NEWS: Actavis to acquire Warner Chilcott

    Generics company Actavis Inc. (NYSE:ACT) will acquire specialty pharma Warner Chilcott plc (NASDAQ:WCRX) in a stock deal that values Warner Chilcott at about $5 billion. Warner Chilcott shareholders will receive 0.16 …

    Published on 5/20/2013
  • COMPANY NEWS: Elan to buy AOP, NewBridge stake, spin out ELND005

    Elan Corp. plc (NYSE:ELN) announced two proposed acquisitions on Monday, including a proposal to buy rare disease company AOP Orphan Pharmaceuticals AG (Vienna, Austria) for EUR 175.7 million ($225.5 million) in cash …

    Published on 5/20/2013
  • COMPANY NEWS: FDA reviewers question safety of Merck's suvorexant

    FDA reviewers said insomnia candidate suvorexant from Merck & Co. Inc. (NYSE:MRK) is effective at promoting sleep, but questioned the product's safety profile as well as the pharma's proposed dosing levels. In briefing …

    Published on 5/20/2013
  • COMPANY NEWS: Bayer submits Japanese application for riociguat

    Bayer AG (Xetra:BAYN) submitted a regulatory application in Japan for riociguat to treat chronic thromboembolic pulmonary hypertension (CTEPH). The oral soluble guanylyl cyclase (sGC) stimulator is under Priority Review…

    Published on 5/17/2013
  • COMPANY NEWS: G-BA rebuffs Pixuvri, Trajenta for second indication

    Germany's Federal Joint Committee (G-BA) issued a final benefit assessment rebuffing diabetes drug Trajenta linagliptin from Boehringer Ingelheim GmbH (Ingelheim, Germany) as add-on therapy to insulin with or without …

    Published on 5/17/2013
  • COMPANY NEWS: TaiGen submits nemonoxacin applications in Taiwan, China

    TaiGen Biotechnology Co. Ltd. (Taipei, Taiwan) submitted a pair of NDAs in Taiwan and China for oral nemonoxacin to treat community-acquired pneumonia (CAP). The company, which said these are the first applications …

    Published on 5/17/2013
  • COMPANY NEWS: Aegerion gains on Juxtapid update

    Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) jumped $14.73 (31%) to $61.70 on Thursday after the company said late Wednesday that the "launch metrics" for Juxtapid lomitapide are ahead of the company's internal plan and …

    Published on 5/16/2013
  • COMPANY NEWS: Evotec, Harvard in antibacterials deal

    Evotec AG (Xetra:EVT) and Harvard University partnered to discover and develop small molecule inhibitors of peptidoglycan biosynthesis. Harvard will contribute research on proprietary assays, chemical starting points …

    Published on 5/16/2013
  • COMPANY NEWS: FDA to discuss QRxPharma's MoxDuo

    FDA's Anesthetic and Analgesic Drug Products Advisory Committee will meet on July 17 to discuss an NDA from QRxPharma Ltd. (ASX:QRX; OTCQX:QRXPY) for MoxDuo IR morphine/oxycodone to treat moderate to severe acute pain. …

    Published on 5/16/2013
  • COMPANY NEWS: G-BA says Adcetris has 'unquantifiable' additional benefit

    Germany's Federal Joint Committee (G-BA) said in a final assessment that lymphoma drug Adcetris brentuximab vedotin from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) has an "unquantifiable" degree of additional benefit. …

    Published on 5/16/2013
  • COMPANY NEWS: IBM, UCB in big data deal for epilepsy

    IBM Corp. (NYSE:IBM) and UCB Group (Euronext:UCB) partnered to develop a point-of-care analytics system to predict the probability of success of epilepsy treatments to inform treatment decisions. The partners said they …

    Published on 5/16/2013
  • COMPANY NEWS: Intra-Cellular appoints Rawlins to board

    Neurology company Intra-Cellular Therapies Inc. (New York, N.Y.) appointed Sir Michael Rawlins, former chairman of the U.K.'s NICE, as a director. Rawlins' term ended on March 31, 2013; he had been chairman since the …

    Published on 5/16/2013
  • COMPANY NEWS: Roche, QB3 partner to launch startups

    Roche (SIX:ROG; OTCQX:RHHBY) partnered with the California Institute for Quantitative Biosciences (QB3) to launch the Collaborative Startups program to identify, fund and support early life science startups in the San …

    Published on 5/16/2013
  • COMPANY NEWS: ABLE questions Indian approval of Cipla biosimilar

    India's Association of Biotechnology Led Enterprises sent a letter to the Drug Controller General of India (DCGI) asking whether the approval of biosimilar Etacept from Cipla Ltd. (Mumbai, India) was based on India's …

    Published on 5/15/2013
  • COMPANY NEWS: Bayer, QB3 partner on life science startups

    The Bayer Healthcare LLC subsidiary of Bayer AG (Xetra:BAYN) partnered with the California Institute for Quantitative Biosciences (QB3) under a three-year deal to evaluate and support life science startups from QB3. The…

    Published on 5/15/2013
  • COMPANY NEWS: FDA approves radium-223 from Bayer, Algeta

    FDA approved an NDA from Bayer AG (Xetra:BAYN) for Xofigo radium-223 dichloride to treat castration-resistant prostate cancer (CRPC) in patients with symptomatic bone metastases. Xofigo is indicated for men whose cancer…

    Published on 5/15/2013

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or never received a password, please click above to receive a new one.

The Daily Extra

Concise and authoritative news for biotech and pharma, written each business day by BioCentury’s senior editors and analysts.


Find out how to get your biopharma daily news update.